Why is Northwest (NWBO) Stuck Under $1 Mark?

  • $2 mark was never reached by NWBO
  • New cancer vaccine production in the UK gives a chance to greater profits
  • Covid-19 age is over

Long-term holding Northwest (NWBO) investors are still quiet about its under $1 value because of short squeeze focused speculators. Within two years of trade, NWBO has never poped over $2 while being the most discussed OTC stock in finance forums. It actually had a chance to soar in 2020 when biotech stocks were conquering the stock exchanges by tanking energy stocks.

Last month Northwest announced the beginning of cancer vaccine production in Sawston, UK. Therefore NWBO started growing after being tanked for several months. However, it is gaining slowly because no recent news has popped out in press releases. Only expected growth in revenue from producing the vaccine gives hope to long-term holders.

Unlike CytoDyn the Northwest stock is entering the bullish area when covid-19 stocks are not trending anymore as we see in the most active movers. a year ago almost half of most active stocks were biotech. Today we see only energy, tech, EV shares are trending.

nwbo stock